Poor formulary communication costs health systems money in ways that rarely show up as a single line item, which is exactly why the problem persists as long as it does.

If you work in oncology or infusion, you already know that biosimilars aren't coming; they're here. For most drugs, your team has figured out the clinical piece. You know the science, you understand interchangeability, and you've read the FDA approvals.

The part that keeps tripping people up isn't clinical. It's communication.

And like I said at the Health Connect Partners event in May (to a room full of chuckles), formulary excites me. 😀 If you don’t believe me, here’s proof...

We're Having a "Make It Make Sense" Moment.